Compare Recursion Pharmaceuticals Inc (RXRX) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs ThredUp Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.41 (market cap $2.14B), while ThredUp Inc trades at $2.47 (market cap $308.63M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 6.9× ThredUp Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, ThredUp Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and ThredUp Inc for 29 Days on average.
| RXRX | TDUP | |
|---|---|---|
Market Cap | $2.14B | $308.63M |
Volume | 30,789,535 | 3,024,364 |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $9.41 |
52-Week Low | $2.84 | $2.12 |
Typical Hold Time | 23 Days | 29 Days |
Enterprise Value | $1.66B | $306.81M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
ThredUp (TDUP) trades at $2.48, up 11.71% in the last session, yet remains in a bearish technical trend. The company reported record Q2 2026 revenue of $90.8 million, up 17% year-over-year, but missed EPS estimates and cut full-year revenue guidance. Despite a high gross margin of 79.52%, it posted a net loss margin of -6.65% and negative ROE. Analyst consensus is 57% buy, but recent news highlights a fraud investigation and promotional headwinds.
The outlook is mixed: strong revenue growth and a dominant position in online resale offer upside, but persistent losses, weak guidance, and legal risks pose significant challenges. Investors should weigh the bullish analyst ratings against fundamental weaknesses and recent stock volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
